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Hepatitis C virus core protein triggers expansion and
activation of CD41CD251 regulatory T cells in chronic
hepatitis C patients
Naicui Zhai1, Xiumei Chi2, Tianyang Li1, Hongxiao Song1, Haijun Li1, Xia Jin3, Ian Nicholas Crispe4,
Lishan Su1,5, Junqi Niu2 and Zhengkun Tu1,2
CD41CD251FoxP31 regulatory T cells (Tregs) are increased in patients with chronic hepatitis C, which may contribute to
the sustained suppression of hepatitis C virus (HCV)-specific T-cell responses and viral persistence in HCV-infected
individuals. We postulated that HCV core protein (HCVc) directly contributes to the expansion of Tregs in HCV-infected
patients, and we provide evidence to support this hypothesis in the report. Peripheral blood mononuclear cells (PBMCs)
and sera were collected from 87 treatment-naı̈ve chronic HCV-infected patients, CD41CD251 Tregs were measured by
flow cytometry, and HCV RNA and HCVc levels were detected using qPCR and enzyme-linked immunosorbent assay
(ELISA), respectively. CD41, CD81, CD41CD251 and CD41CD252 T cells were purified from healthy donors and
cultured with recombinant HCVc and Toll-like receptor (TLR) ligands. Flow cytometry was used to analyze cell
proliferation, and ELISA was performed to measure cytokine production. In the 87 chronic HCV-infected patients, HCVc
showed a significant correlation with HCV RNA and CD41CD251 Tregs. Mechanistic studies showed that HCVc, together
with anti-CD3 antibody, augmented CD41CD251 Treg proliferation, but inhibited CD41CD252 T-cell proliferation and
IFN-c production, in a dose-dependent and Treg-dependent manner. Moreover, unlike the TLR3 ligand (poly I:C) and the
TLR4 ligand (lipopolysaccharide, LPS), the TLR2 ligand (lipoteichoic acid, LTA) and HCVc both inhibited TCR-induced
CD41 T-cell proliferation and IFN-c secretion in a Treg-dependent manner. These data indicate that HCVc, like other
TLR2 ligands, triggers CD41CD251 Treg activation and expansion to inhibit host immune responses, which may play a
critical role in viral persistence in HCV-infected patients.
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INTRODUCTION
Chronic viral hepatitis due to hepatitis C Virus (HCV) is
accompanied by immune failure. Features of this failure
include the persistence of viremia, the exhaustion of effector
T cells and the increased activity of regulatory T cells (Tregs).1–5
However, the relationships between these biomarkers of
immune failure are not entirely clear. We sought to clarify these
relationships through a study of T cells isolated from a cohort
of 87 HCV-infected patients.
We focused on the core protein of hepatitis C virus (HCVc)
because it mediates diverse immunosuppressive effects. One of
these actions is mediated by binding to the Toll-like receptor 2
(TLR2) pattern recognition receptor of Kupffer cells. In this
context, HCVc induces diverse pro-inflammatory and anti-
inflammatory cytokines but strongly inhibits the secretion of
the anti-viral cytokines IFN-a and IFN-b and inhibits the upre-
gulation of the TNF receptor-associated apoptosis-inducing
ligand on the cell surface.6 The HCVc protein also engages
TLR2 on human dendritic cells, skewing their differentiation
with increased expression of both macrophage markers, and
PD-L1.7
Tregs isolated from HCV-infected patients are immunosup-
pressive and can inactivate both HCV-specific and bystander
CD41 and CD81 T cells.8,9 Here, we show that the concentration
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of HCVc in the blood of HCV-infected patients directly corre-
lates with the frequency of Tregs. Furthermore, HCVc directly
caused proliferation of Tregs and caused them to secrete
immunosuppressive cytokines.
While it was previously documented that HCVc inhibits T-
cell proliferation,10 here we reveal the mechanism: HCVc
inhibited CD41 T-cell proliferation and IFN-c secretion in a
Treg-dependent manner. Both of these effects were also seen
with the TLR2 ligand lipoteichoic acid (LTA). Therefore, we
conclude that these effects of HCVc on T cells are also mediated
by TLR2.
These results clarify the multifaceted problem of immuno-
suppression and exhaustion in the context of chronic HCV
infection and may also shed light on the immunology of other
chronic infections, such as hepatitis B Virus infection, in which
exhausted effector T cells co-exist with Tregs.11 Therapeutic
interventions to reverse exhaustion and initiate immunological
self-cure in chronic hepatitis patients depend on a full under-
standing of these mechanisms.
MATERIALS AND METHODS
Samples
Eighty-seven treatment-naive chronic HCV-infected patients
were enrolled in this study (Table 1). Venous blood was with-
drawn for serum and peripheral blood mononuclear cells
(PBMCs) collection. These studies were approved by the IRB
of Jilin University, The First Hospital. Buffy coats from five
healthy donors were provided by the Changchun Blood
Center, and informed consent was provided according to the
protocols of the Changchun Blood Center.
Serum viral load and HCVc level assay
HCV RNA was detected using the Cobas-TaqMan assay or
Amplicor-HCV-Monitor (Roche Diagnostics, Mannheim,
Germany). HCVc was quantified by automated immunoassay
(i System i2000, Architect; Abbott, Wiesbaden, Germany).
HCVc, TLR agonists and reagents
Recombinant HCVc (aa 2–192 of the HCV polyprotein) was
purchased from Biodesign (Saco, ME, USA); TLR agonists
LTA, poly I:C and lipopolysaccharide (LPS) were purchased
from Invivogen (San Diego, CA, USA).
Limulus amebocyte lysate assay for detection of LPS
contamination
The QCL-1000 chromogenic LAL endpoint assay (Cam-brex,
Cottonwood, AZ, USA) was used to detect endotoxin contami-
nation of HCVc following the manufacturer’s protocol as
described.6,7 Briefly, protein-free, phenol-water extracted
ultrapure Escherichia coli LPS was used to create a linear stan-
dard curve from 1 to 100 pg/ml. HCVc was serially diluted to
determine a concentration of agonist within the standard curve
of the assay. HCVc preparations were determined to have
,1 pg/ml LPS contamination.
Isolation of T lymphocyte subsets from peripheral blood
PBMCs were isolated by Ficoll/Paque density gradient centrifu-
gation. For magnetic cell sorting, the CD8 Multisort kit
(Miltenyi Biotec, Bergisch Gladbach, Germany) was used for
the purification of CD81 T cells without ligation of any of their
surface molecules. The CD41CD251 Treg Isolation kit was used
for the purification of CD41 T cells, CD41CD252 T cells and
CD41CD251 Tregs. The purity of the T-cell subsets was deter-
mined by flow cytometry and was always in the 90%–95% range.
Enzyme-linked immunosorbent assay (ELISA)
Concentrations of IFN-c, IL-10 and TGF-b in cell culture
supernatants were measured by ELISA according to the man-
ufacturer’s instructions.6,7
T lymphocyte subsets proliferation assays
CD81, CD41, CD41CD251 Treg and CD41CD252 T- cell
subsets were stained with 5 mM CFSE (Molecular Probes,
Grand Island, NY. USA) according to the manufacturer’s
recommended protocol. CD3 activation was performed by using
10 mg/ml OKT3 (CD3 mAb; eBioscience, San Diego, CA. USA)
bound to the plastic in the wells for subsequent cross-linking
of the T-cell receptors on responding T cells. Plates could also
be prepared the night before an experiment and kept in the
refrigerator overnight. CFSE-labeled T lymphocyte subsets were
cultured in wells pre-coated with OKT3 in the presence of
HCVc and/or TLR agonists. After 5 days, when clumps were
visible, cells were collected and stained with anti-CD25-APC
(BD Biosciences, San Jose, CA, USA), and the proliferating T
lymphocyte subsets were characterized by flow cytometry.
Flow cytometry
Staining of cells and analysis on a flow cytometer (FACScan;
BD Biosciences) were done as described.6,7 CD41CD251 Tregs
were identified using the following anti-human mAb: FITC
Mouse Anti-Human CD4 (Clone: RPA-T4), APC Mouse
Anti-Human CD25 (Clone: M-A251) and PE Mouse Anti-
Human FoxP3 (Clone: 259D/C7). Intracellular FoxP3 staining
Table 1 Characteristics of study population
HCVc serum level (fmol/l)
,1000 1000–5000 .5000
Age, years
(mean6s.e.m.) 48.9615.1 45.5610.9 48.2616.44
Sex
Female/male 20/24 11/13 8/11
ALT, IU/ml
(mean6s.e.m.) 71.2169.36 68.24620.73 60.34613.94
HCV-DNA
(mean6s.e.m.) 4.863105 3.053106 1.113107
61.983105 66.013105 62.533106
HCV genotype
(2a/1b/n.a) 29/11/4 13/10/1 14/5/0
Abbreviations: n.a.: not applicable; SEM: standard error of mean.
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and cell surface CD4 and CD25 staining were performed
according to the manufacturers recommended protocol. All
the antibodies were obtained from BD Biosciences. The data
acquired were analyzed with FlowJo (Treestar software,
Ashland, OR, USA).
Statistical analysis
All data were analyzed and found to be significant using the
D’Agostino and Pearson omnibus normality test. Mean values
were compared using either a paired t-test (two groups) or
ANOVA (.two groups), followed by a Bonferroni correction
for multiple comparisons test. P values ,0.05 were considered
to be significant. All statistical tests were performed by Prism
software (GraphPad, San Diego, CA, USA).
RESULTS
HCVc correlation with HCV RNA and CD41CD251 Tregs
A cohort of 87 treatment-naive chronic HCV-infected patients
was enrolled in this study and divided into three groups based
on serum HCVc levels (44 with HCVc levels ,1000 fmol/l, 24
with HCVc levels between1000 and 5000 fmol/l and 19


































































































Figure 1 Correlation of HCVc levels with that of HCV RNA and CD41CD251 Tregs. Data are shown for 87 treatment-naive chronic HCV-infected
patients. Serum HCV RNA and HCVc levels were detected using qPCR and ELISA, respectively. The frequency of CD41CD251 Tregs from PBMCs
was measured by flow cytometry. A positive correlation was shown between the serum level of HCVc and HCV RNA (r250.44, P,0.001) (a). The 87
chronic HCV-infected patients were divided into three groups according to serum HCVc levels (19 with HCVc level .5000 fmol/l, 24 with HCVc level
1000–5000 fmol/l and 44 with HCVc level ,1000 fmol/l). The correlation between serum HCVc levels and the serum level of HCV RNA (b), ALT (c)
or the frequency of CD41CD251 Tregs from PBMCs (d), was also analyzed. HCV, hepatitis C virus; HCVc, HCV core protein; PBMC, peripheral
blood mononuclear cell; Treg, regulatory T cell.
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RNA and HCVc levels were detected using qPCR and ELISA,
respectively.
Figure 1a and b show that HCVc levels positively correlate
with HCV RNA levels (r250.44, P,0.001), but not with ALT
levels (r250.017, P50.2245) (Figure 1c and d), indicating that
HCVc concentration represents a stable and reliable marker of
HCV viral replication. CD41CD251 Tregs from PBMCs of
chronic HCV-infected patients were measured by flow cytome-
try. Intracellular FoxP3 staining showed that 87% of the
CD41CD251 Tregs, 11% of the CD41CD25dim cells and
0.81% of the CD41CD252 cells are FoxP31 (Supplementary
Figure 1). The frequency of CD41CD251 Tregs was positively
correlated with serum HCVc levels (r250.497, P,0.001)
(Figure 1e). Further analysis shows that the frequency of
CD41CD251 Tregs was significantly higher among the 19
chronic HCV-infected patients with HCVc levels .5000 fmol/
l (4.10760.1693, N519) than in the 24 with HCVc levels
between 1000 and 5000 fmol/l (3.16760.1452, N524)
(P,0.001) and the 44 with HCVc levels ,1000 fmol/l
(2.35260.1093, N544) (P,0.001) (Figure 1f and
Supplementary Figure 2). These results suggest that the HCV-
encoded core protein circulating in the blood may induce the
expansion of natural CD41CD251 Tregs or stimulate their
generation from CD41 T cells.
HCVc induces proliferation of CD41CD251 Tregs
In order to analyze the effects of HCVc on the proliferation of
CD41CD251 Tregs, freshly isolated CD41, CD41CD251
Tregs and CD41CD252 T cells from healthy HCV-negative
blood donors were activated by anti-CD3 mAb for 5 days in
the presence of increasing concentrations of HCVc protein.
Our results show that HCVc induced CD41CD251 Treg pro-
liferation in a dose-dependent manner but inhibited total
CD41 T-cell proliferation (Figure 2b). However, depletion of
CD41CD251 Tregs from the total CD41 T-cell population
abrogated the inhibitory effect of HCVc on anti-CD3-induced
CD41 T-cell proliferation (Figure 2a and b) supplementary
Figure 3. Additionally, HCVc alone did not induce T-cell
proliferation (data not shown). These data suggest that the
HCVc protein may stimulate Tregs to actively suppress other
CD41 T cells.
HCVc induced production of IL-10 and TGF-b in
CD41CD251 T cells and inhibited IFN-c production in
CD41 T cells through CD41CD251 Tregs
To test whether HCVc affected Treg function and to assess its
effects on IFN-c secretion from other T cells, freshly isolated
HCV-negative, human CD41, CD41CD251 Tregs and










































Figure 2 HCV core protein induces CD41CD251 T-cell proliferation. Primary CD41 T cells were isolated from peripheral blood of healthy donors by
using a CD4 isolation kit first, and further purification of CD41CD251 and CD41CD252 T cells was performed by using a Treg isolation kit according
to the manufacturer’s instructions. The purified total CD41, CD41CD251 and CD41CD252 T cells were labeled with CFSE and then cultured for 5
days in plates pre-coated with OKT3 (CD3 mAb) and various concentrations of HCVc. Flow cytometry was used to analyze cell proliferation.
Representative experiment results from one donor out of five are shown (a) and the percentage of cell proliferation as mean6s.d. from five separate
experiments are also shown (b) (n55, *P,0.05, **P,0.01). HCV, hepatitis C virus; HCVc, HCV core protein; Treg, regulatory T cell.
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absence or presence of HCVc for 2 days. We found that HCVc
inhibited TCR-induced IFN-c secretion of CD41 T cells in a
dose-dependent manner, and depletion of CD41CD251 Tregs
from the CD41 T cells abrogated the inhibitory effect of HCVc
on IFN-c production. HCVc did not induce IFN-c production
in CD41CD251 Tregs (Figure 3a). More importantly, we also
found that HCVc induced IL-10 and TGF-b secretion by
CD41CD251 Tregs, but showed no effect on cytokine produc-
tion by CD41CD252 T cells (Figure 3b and c).
HCVc and LTA inhibit the proliferation of CD41 T cells in a
Treg-dependent fashion
HCVc is a ligand for TLR2, which induces the production of
inflammatory cytokines by activating the MyD88-dependent
TLR signaling pathway.12 Therefore, we further examined
whether HCVc triggers the expansion and activation of
CD41CD251 regulatory T cells via TLR2 signaling. CD41 T
cells and CD81 T cells were purified from the peripheral blood
of healthy donors by CD4 and CD8 microbeads and then acti-
vated by anti-CD3 mAb and ligands of TLR2, TLR3 and TLR4
(LTA, poly I:C and LPS, respectively) in the absence or presence
of HCVc. The results showed that the TLR2 ligand LTA, like
HCVc, inhibited the proliferation of CD41 T cells, but poly I:C
and LPS did not affect CD41 T-cell proliferation (Figure 4a and
c). In addition, neither HCVc nor any of the ligands of TLR2,
TLR3 and TLR4 affected the proliferation of purified CD81 T
cells (Figure 4b and d).
LTA and HCVc inhibit IFN-c production in TCR-activated
CD41 T cells
To explore whether LTA also inhibits IFN-c secretion in CD41
T cells through CD41CD251 Tregs, total CD41 T cells and
CD41CD252 T cells were purified from healthy HCV-negative
donors and activated by anti-CD3 mAb and TLR2, TLR3 and
TLR4 ligands for 2 days in the presence of HCVc as described
above. We found that neither TLR2, TLR3 and TLR4 ligands
nor HCVc alone induced CD41 T-cell IFN-c production,
whereas anti-CD3 mAb induced IFN-c secretion from both
CD41 and CD41CD252 T cells (Figure 5). However, LTA
and HCVc inhibited anti-CD3 mAb-induced IFN-c secretion
from CD41 T cells, but not from CD41CD252 T cells. Poly I:C
and LPS did not affect IFN-c secretion in TCR-activated CD41
T cells. Therefore, HCVc inhibited CD41 T-cell activation in a
Treg-dependent fashion.
DISCUSSION
CD41CD251FoxP31 Tregs are increased in patients with
chronic hepatitis C, and this may mediate the sustained sup-
pression of HCV-specific T-cell responses and the viral persis-
tence in HCV-infected individuals.13–15 The mechanism of
Treg proliferation and its activity in HCV infection are not
completely understood. In the current study, we confirm that
HCVc showed a significant, positive correlation with HCV
RNA and the frequency of CD41CD251 Tregs in 87 chronic
HCV-infected patients. Furthermore, we evaluated the role of
HCVc in Treg proliferation and suppressive functions and
found that HCVc induced CD41CD251 Treg proliferation
and IL-10 and TGF-b secretion in a dose-dependent manner.
Moreover, HCVc inhibited CD41 T-cell proliferation and IFN-
c production in a Treg-dependent fashion. In addition, a TLR2
agonist, LTA, inhibited CD41 T-cell proliferation and IFN-c
production to the same extent as HCVc did, but poly I:C (TLR3
agonist) and LPS (TLR4 agonist) did not. These results suggest
that HCVc, as a ligand for TLR2, may play a role in activating
Treg proliferation and inducing their suppressive function.
This mechanism may contribute to the sustained suppression
of HCV-specific T-cell responses and the consequently persist-
ent HCV infection.
HCV has developed different strategies to evade the host’s
innate and adaptive immune responses. HCV has been shown
to interfere with innate antiviral defenses through multiple
mechanisms. HCVc protein induces the expression of SOCS-
3, which suppresses JAK-STAT signaling. Also, the NS3/4A






















































Figure 3 HCVc induces IL-10 and TGF-b production in CD41CD251 T
cells and inhibits IFN-c production in CD41 T cells through
CD41CD251 T cells. Total CD41, CD41CD251 and CD41CD252 T
cells were cultured for 2 days in wells pre-coated with OKT3 (CD3
mAb) and various concentrations of HCVc. The supernatants were then
harvested and assayed by ELISA for IFN-c (a), IL-10 (b) and TGF-b (c)
levels (n55, *P,0.05, **P,0.01). HCVc, HCV core protein.
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expression by blocking RIG-I and TLR3 signaling.16,17 In addi-
tion, HCV proteins have been shown to upregulate TLR2 and
TLR4 expression on Raji cells and peripheral blood mononuc-
lear cells, thereby modulating the cell’s pro-inflammatory res-
ponse.18,19 Moreover, several studies by our group and others
have provided evidence that the HCV core can activate TLR2
on human monocytes, macrophages and Kupffer cells, which
induces production of inflammatory cytokines by activating
the MyD88-dependent TLR signaling pathway.6,12,19 An effect
of HCV core expression on CD41 T cells has been reported,
showing that this protein induces a state of unresponsiveness
similar to clonal anergy or T-cell exhaustion.20–22 HCVc can
bind the human complement receptor C1qR, thus inhibiting
T-cell responses.23,24 More recently, using a lentiviral vector to
express HCVc in CD41 Jurkat T cells, Dominguez-Villar et al.25
report that FoxP3 and CTLA-4 (cytotoxic T-lymphocyte
antigen-4) were upregulated in HCVc-expressing Jurkat cells
and that HCVc-transfected Jurkat cells were able to suppress
CD41 and CD81 T-cell responses to anti-CD3 plus anti-CD28
stimulation.25 In agreement with these findings, our results
showed that HCVc inhibited CD41 T-cell proliferation and
IFN-c production in the presence of anti-CD3 mAb, and fur-
ther mechanistic studies showed that HCVc triggers
CD41CD251 Treg expansion and activation to mediate the
inhibition.
Our results shed new light on the expansion of Treg cells by
HCVc and provide evidence that this HCV protein is respon-
sible for enhanced Treg activity in the periphery during chronic
HCV infections. Interestingly, the canonical TLR2 ligand lipo-
teichoic acid had the same effect on Tregs as HCVc, suggesting
that other pathogens that engage TLR2 may also induce the
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Figure 4 Both HCVc and LTA inhibit the proliferation of CD41 T cells but not CD81 T cells. Primary CD41 T cells and CD81 T cells were purified,
and CFSE-labeled CD41 and CD81 T cells were cultured for 5 days in wells pre-coated with OKT3 (CD3 mAb) and HCVc in the presence of different
TLR ligands. Flow cytometry was used to analyze cell proliferation. Representative experiment results from one donor out of five are reported in (a)
and (b), and the percentage of proliferating CD41 and CD81 T cells and mean6s.d. from five separate experiments are shown as (c) and (d) (n55,



















































































Figure 5 HCVc and LTA inhibit IFN-c production by activated CD41 T
cells in a Treg-dependent fashion. Purified CD41 and CD81 T cells were
cultured with pre-coated OKT3 (CD3 mAb) and HCVc and TLR ligands
for 2 days. The supernatants were then harvested and assayed by ELISA
for IFN-c levels (n55, *P,0.05, **P,0.01). HCVc, HCV core protein;
LTA, lipoteichoic acid; Treg, regulatory T cell; TLR, Toll-like receptor.
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